CYT Cyteir Therapeutics Inc

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 3, 2023

 

 

Cyteir Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware			001-40499	45-5429901
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
99 Hayden Street, Building B, Suite 450
Lexington, Massachusetts				02421
(Address of Principal Executive Offices)				(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 857 285-4140

 

128 Spring Street, Building A, Suite 510, Lexington, Massachusetts, 02421

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value per share		CYT		The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

---

 

Item 1.01 Entry into a Material Definitive Agreement.

 

On October 3, 2023, Cyteir Therapeutics, Inc. (the “Company”), entered into a Lease Amendment (the “Amendment”) between the Company and 99 Hayden LLC, which amends the Lease dated August 8, 2018 (as amended by that certain First Amendment to Lease dated as of October 15, 2019, Second Amendment to Lease dated July 1, 2021, and Lease Amendment and Termination Agreement dated March 29, 2023, the “Lease”), between the Company and 99 Hayden LLC, related to office space located at Ledgemont Technology Center at 99 Hayden Avenue, Lexington, Massachusetts. The Amendment extends the term of the Lease for an additional one-month term, commencing on November 1, 2023 and expiring on November 30, 2023. Under the terms of the Amendment, the Company will continue to lease 5,531 square feet of office space pursuant to the Lease, which will continue to serve as the Company's principal executive office during the extended term.

 

The foregoing description is a summary of certain material terms of the Amendment and is qualified in its entirety by the text of the Amendment, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

 

Exhibit No.		Description
10.1		Fourth Lease Amendment between 99 Hayden LLC and Cyteir Therapeutics, Inc., dated as of October 3, 2023

 

 

---

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

			CYTEIR THERAPEUTICS, INC.
Date:	October 5, 2023	By:	/s/ David Gaiero
			Name: David Gaiero Title: Chief Financial Officer and Treasurer

 

---

Exhibit 10.1

LEDGEMONT TECHNOLOGY CENTER

Lexington, Massachusetts

 

FOURTH AMENDMENT TO LEASE CYTEIR THERAPEUTICS, INC.

 

Fourth Amendment to Lease (“Fourth Amendment”) dated as of October 3 , 2023 between 99 Hayden LLC, a Delaware limited liability company (“Landlord”), and Cyteir Therapeutics, Inc., a Delaware corporation (“Tenant”).

 

Background

 

WHEREAS, Landlord’s predecessor in interest, 128 Spring Street Lexington, LLC, a Delaware limited liability company, and Tenant entered into a certain Lease dated August 8, 2018 (the “Original Lease”), as amended by that certain First Amendment to Lease dated as of October 15, 2019 (the “First Amendment”), Second Amendment to Lease dated July 1, 2021 (the “Second Amendment”), and Lease Amendment and Termination Agreement dated March 29, 2023 (the “Third Amendment”) (collectively the “Lease”), between Landlord and Tenant for certain premises consisting of approximately 5,531 rentable square feet of which is known as Suite 450 located on the 400 Level of the B Building (“Suite 450B”) (the “Premises”) of Ledgemont Technology Center at 99 Hayden Avenue, Lexington, Massachusetts (the “Building”). Capitalized terms used and not otherwise defined in this Fourth Amendment shall have the meanings ascribed to them in the Lease.

 

The Lease is scheduled to expire October 31, 2023. Landlord and Tenant desire to enter into this Fourth Amendment to extend the Term of the Lease on the terms more particularly set forth in this Fourth Amendment.

 

Agreement

 

FOR VALUE RECEIVED, Landlord and Tenant agree as follows:

 

 

 

 

 

1

---

Exhibit 10.1

450B of the Premises only shall be due and payable in a monthly installment as provided in the Lease, in the following amounts:

 

Month of Term	Monthly Base Rent
November 1, 2023 – November 30, 2023	$14,057.96

 

 

 

 

 

 

(ii) Tenant has no rights to any credit, claim, cause of action, offset or similar charge against Landlord or the Base Rent existing as of the date hereof, and (iii) without Landlord’s prior written consent, there have been no assignees, sublessees or transferees of the Lease, or any person or firm occupying or having the right in the future to occupy the Premises, or any part thereof, except Tenant.

 

2

 

---

Exhibit 10.1

consent to a party’s accountants, attorneys, employees, agents, potential transferees and lenders, and others in privity with such party to the extent reasonably necessary for such party’s business purposes, or in connection with a dispute hereunder, provided that such party has been expressly advised of the confidential nature of such information.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

3

 

---

Exhibit 10.1

EXECUTED as a sealed Massachusetts instrument as of the date first written above.

 

 

LANDLORD:

 

99 Hayden LLC,

a Delaware limited liability company

 

 

By: /s/ Peter Gottlieb

Name: Peter Gottlieb

Title: Manager

 

TENANT:

 

Cyteir Therapeutics, Inc., a Delaware corporation

 

 

By: /s/ Markus Renschler

Name: Markus Renschler

Title: President and CEO

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

4

 

---

v3.23.3

Document and Entity Information	Oct. 03, 2023
Cover [Abstract]
Amendment Flag	false
Entity Central Index Key	0001662244
Document Type	8-K
Document Period End Date	Oct. 03, 2023
Entity Registrant Name	Cyteir Therapeutics, Inc.
Entity Incorporation State Country Code	DE
Securities Act File Number	001-40499
Entity Tax Identification Number	45-5429901
Entity Address, Address Line One	99 Hayden Street, Building B
Entity Address, Address Line Two	Suite 450
Entity Address, City or Town	Lexington
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02421
City Area Code	857
Local Phone Number	285-4140
Written Communications	false
Soliciting Material	false
Pre Commencement Tender Offer	false
Pre Commencement Issuer Tender Offer	false
Security 12b Title	Common Stock, $0.001 par value per share
Trading Symbol	CYT
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	true
Entity Ex Transition Period	false

---